Giulia Spoletini

Dr. Giulia Spoletini


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2015 in Chest
Verified
Journal Article
Closed access
PDF file
GSGiulia Spoletini
Giulia Spoletini
MAMona Alotaibi
Mona Alotaibi
Francesco BlasiFrancesco Blasi
Francesco Blasi
NHNicholas S. Hill
Nicholas S. Hill

1 December 2018 in Journal of Critical Care
Verified
Journal Article
Closed access
GSGiulia Spoletini
Giulia Spoletini
CMChiara Mega
Chiara Mega
LPLara Pisani
Lara Pisani
MAMona Alotaibi
Mona Alotaibi
AKAlia Khoja
Alia Khoja
NHNicholas S. Hill
Nicholas S. Hill

11 January 2019 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
GSGiulia Spoletini
Giulia Spoletini
CEC Etherington
C Etherington
NSN Shaw
N Shaw
ICI J Clifton
I J Clifton
MDM Denton
M Denton
DPD G Peckham
D G Peckham
The efficacy of antibiotic treatment in pulmonary and systemic infections in cystic fibrosis (CF) is limited by the increased prevalence of MDR strains of Pseudomonas aeruginosa and Burkholderia cepacia complex. Ceftazidime/avibactam is a new combination which, in vitro, appears to have good activity against MDR strains of P. aeruginosa and B. cepacia complex. A retrospective analysis was performed including adult patients with CF who received at least one course of ceftazidime/avibactam owing to pulmonary exacerbations not responding to conventional antibiotic treatment. Treatment with ceftazidime/avibactam was associated with reduction in inflammatory markers and improvement in lung function. No episodes of acute kidney injury or elevation in transaminase were observed. Ceftazidime/avibactam appeared to be well tolerated and improved patients' outcomes. Further studies are needed to better assess the role of this new combination in CF.

31 May 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HJHeledd H. Jarosz-Griffiths
Heledd H. Jarosz-Griffiths
LGLindsey Gillgrass
Lindsey Gillgrass
LCLaura R. Caley
Laura R. Caley
GSGiulia Spoletini
Giulia Spoletini
ICIan J. Clifton
Ian J. Clifton
DPDaniel Peckham
Daniel Peckham
Inflammation is a key driver in the pathogenesis of cystic fibrosis (CF). We assessed the effectiveness of elexacaftor/tezacaftor/ivacaftor (ETI) therapy on downregulating systemic and immune cell-derived inflammatory cytokines. We also monitored the impact of ETI therapy on clinical outcome. Adults with CF, heterozygous for F508del (n = 19), were assessed at baseline, one month and three months following ETI therapy, and clinical outcomes were measured, including sweat chloride, lung function, weight, neutrophil count and C-reactive protein (CRP). Cytokine quantifications were measured in serum and following stimulation of peripheral blood mononuclear cells (PBMCs) with lipopolysaccharide (LPS) and adenosine triphosphate and analysed using LEGEND plex™ Human Inflammation Panel 1 by flow cytometry (n = 19). ASC specks were measured in serum and caspase-1 activity and mRNA levels determined from stimulated PBMCs were determined. Patients remained stable over the study period. ETI therapy resulted in decreased sweat chloride concentrations (p < 0.0001), CRP (p = 0.0112) and neutrophil count (p = 0.0216) and increased percent predicted forced expiratory volume (ppFEV1) (p = 0.0399) from baseline to three months, alongside a trend increase in weight. Three months of ETI significantly decreased IL-18 (p< 0.0011, p < 0.0001), IL-1β (p<0.0013, p = 0.0476), IL-6 (p = 0.0109, p = 0.0216) and TNF (p = 0.0028, p = 0.0033) levels in CF serum and following PBMCs stimulation respectively. The corresponding mRNA levels were also found to be reduced in stimulated PBMCs, as well as reduced ASC specks and caspase-1 levels, indicative of NLRP3-mediated production of pro-inflammatory cytokines, IL-1β and IL-18. While ETI therapy is highly effective at reducing sweat chloride and improving lung function, it also displays potent anti-inflammatory properties, which are likely to contribute to improved long-term clinical outcomes.

1 January 2016 in Annals of Thoracic Medicine
Verified
Journal Article
Open access
PDF file
NHNicholas S. Hill
Nicholas S. Hill
GSGiulia Spoletini
Giulia Spoletini
Ann Thorac Med, Official scientific journal of Saudi Thoracic society

1 April 2022 in ERJ Open Research
Verified
Journal Article
Open access
PDF file
GSGiulia Spoletini
Giulia Spoletini
GFGiles Fitch
Giles Fitch
LGLindsey Gillgrass
Lindsey Gillgrass
CEChristine Etherington
Christine Etherington
ICIan Clifton
Ian Clifton
DPDaniel G. Peckham
Daniel G. Peckham
Pseudo-Bartter syndrome (PBS) is characterised by hypokalaemic, hyponatraemic and hypochloraemic metabolic alkalosis in the absence of renal tubules pathology; it is a well-recognised complication of cystic fibrosis (CF), in the context of dehydration and acute illness [1–7].